Celldex Therapeutics (CLDX) Equity Ratio (2010 - 2026)

Celldex Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.89 for Q1 2026.

• In Q1 2026, Equity Ratio fell 6.13% year-over-year to 0.89; the TTM figure through Mar 2026 stood at 0.89 (down 6.13% YoY), while the FY2025 annual figure was 0.9, down 4.09% from the prior year.
• Equity Ratio was 0.89 for Q1 2026 at Celldex Therapeutics, down from 0.9 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2024 to a low of 0.88 in Q3 2023.
• Historically, Equity Ratio has averaged 0.93 across 5 years, with a median of 0.93 in 2023.
• The sharpest annual moves came in 2024 and 2026: Equity Ratio climbed 8.45% in 2024, then dropped 6.13% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.92 in 2022, then decreased by 0.33% to 0.92 in 2023, then advanced by 2.29% to 0.94 in 2024, then fell by 4.09% to 0.9 in 2025, then declined by 1.31% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.9 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.